Presentation is loading. Please wait.

Presentation is loading. Please wait.

PhD Student: NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169 Department of Clinical Pharmacy Pharmacokinetics and Drug Evaluation Laboratory.

Similar presentations


Presentation on theme: "PhD Student: NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169 Department of Clinical Pharmacy Pharmacokinetics and Drug Evaluation Laboratory."— Presentation transcript:

1 PhD Student: NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169 Department of Clinical Pharmacy Pharmacokinetics and Drug Evaluation Laboratory Lyon 1 University –

2  Autoimmune diseases: arise from an overactive immune response of the body against its cell.  Inflammatory bowel disease (IBD): a group of disorders in which the intestines become inflamed  Autoimmune hepatitis (AIH): the immune systems attacks liver cells  Dermatology diseases: Skin diseases  Azathioprine (AZA): - an immunosuppressive drug, complex metabolism 6-TGN: an active metabolite, pmol/ RBCs: therapeutic range Limited data: on AZA dose for children OBJECTIVES Suggest AZA dose for children Evaluate efficacy, toxicity in function of AZA dose and 6TGN level INTRODUCTION - OBJECTIVES

3 AZA METABOLISM AZA 6MP 6-MeMP 6-TGMP 6-TGDP 6-TGTP 6-TGN Active metabolite TPMT Inactive metabolite, TOXICITY Most active Mono P Di P Tri P 6-TUA XOD

4 AZA DOSE FOR IBD CHILDREN  Objective: - Suggest AZA dose for pediatric IBD patients - Investigate efficacy, toxicity in function of AZA dose and 6-TGN level  Method: 64 patients less than 19 years received AZA mono-therapy for at least 3 months - 3 dose groups: below 2, (standard dose), greater than 2.5 mg/kg/d - Remission: PCDAI <10 - Toxicity: Leukopenia; Lymphopenia; Hepatotoxicity, Pancreatotoxicity - Metabolite assay (6-TGN, Me6-MPN): HPLC 1st year -AZA dose below 2 mg/kg/d appears effective in pediatric patients (94%) - Children may achieve remission when 6-TGN level below 250 nmol/h/mL RBCs (85%) - Therapeutic range pmol/ RBCs seems not appropriate Further Studies RESULTS

5 INFLUENCE OF AGE ON UTILITY OF AZA DOSE IN IBD CHILDREN  Our 1st study: suggest dose for IBD children less than 19 years AZA dose less than 2 mg/kg/d is effective  1 published study: suggest dose greater than 3 mg/kg/d for children 6 years old or younger Now Investigate influence of age on AZA efficacy and toxicity in function of AZA dose and 6-TGN level Method: -Divide studied population into 2 age groups: the adolescent ( more than 11 years), the young children (11 years and younger) - Data of each groups is subdivided into groups of AZA dose: Below 2 mg/kg/d, mg/kg/d, more than 2.5 mg/kg/d

6 STUDY ON AZA THERAPY IN CHILDREN WITH SOME OTHER AUTOIMMUNE DISEASES  Autoimmune Hepatitis (AIH) and Dermatology diseases Next years Collect pediatric patients treated with AZA Evaluate efficacy, toxicity - Investigate therapeutic range of 6-TGN level - Optimize AZA dose for children with these diseases  6TGN: - correspond to the mono, di, tri-phosphate forms of 6-Thioguanosine (Tri phosphate form was considered to be the major active compound) Contradictory data on relation between 6-TGN level and efficacy - Develop a method to determine levels of these 6-TGN forms in children - Investigate the relation between each form of 6-TGN and efficacy in children Previous studies determined total 6-TGN levels


Download ppt "PhD Student: NGUYEN Thi Van Anh Supervisor: Prof. Roselyne BOULIEU EA 4169 Department of Clinical Pharmacy Pharmacokinetics and Drug Evaluation Laboratory."

Similar presentations


Ads by Google